5‐Methoxy Psoralen, Etretinate, and UVA for Psoriasis

This first Australasian randomized trial of 5‐methnxy psoralen (5‐MOP) PUVA for psoriasis shows, conclusively, less acute side effects than 8‐MOP PUVA. Daily addition of oral etretinate to the PUVA regimen (Re‐PUVA) produces a valuable reduction in total joules and more so with 5‐MOP than with 8‐MOP. The clearing phase with 5‐MOP Re‐PUVA is quicker than with 8‐MOP Re‐PU VA in skin types 1, 2, and 3 (most Anglo‐Saxon‐Celtic Australians). Doses, when adapted to total body surface rather than mg/kg, allow superior control of therapy. Emollient creams, tar gels, non‐steroidal scalp applications, etc. allow more patient comfort.